Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. NGNE has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
NGNE stock price ended at $18.3 on Wednesday, after losing-0.65%
The Neurogene Inc stock price decreased by -0.65% on the last trading day (18 Jun 2025), dropping from 18.3 to 18.3. Throughout the last trading session, the stock experienced a fluctuation of 7.41% , ranging from a day low of $18.22 to a day high of 19.5699. The price has declined in 8 of the last 10 days, resulting in a total change of -15.55% during this period. On the last day, trading volume increase by 51.43K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 203.61K shares were traded, amounting to approximately 3.84M.
NGNE Technical Signals
NGNE(Neurogene Inc Corp) has 4 buy signals and 2 sell signals now. The current trend is downtrend starting from 2025-06-06. The total price change during this trend is -16.17%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of NGNE over the last 5 trading days is 2.97M. Overall, the technical indicator signals lean more toward a Bullish outlook in the mid-term.
NGNE Moving Average Analysis
Neurogene Inc's overall moving average trend leans more bearish as of Friday, June 20, 2025, with 3 negative signals and 1 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $25.54446, and $28.207. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $16.929539999999996, and $14.266999999999996. A break-down below any of these levels will issue sell signals.
NGNE Short Selling Analysis
The short sale ratio of Neurogene Inc(NGNE) as of 17 Jun 2025 is 20.27%, dropping from last trading day. With decreasing price from 18.97 to 18.42. The short sell activity indicate that short sellers may be anticipating price hit a bottom.
Technical Signal
Technical Signals Summary
Sell
2
Buy
4
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
4 Bullish Signals
4 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
1.851
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.778
Bullish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 < 20
0
Bullish
Williams %R (14 days)
WILLR_14 < -80
-80.367
Bullish
2 Bearish Signals
2 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Momentum (10 days)
MOM_10 < 0
-3.37
Bearish
Moving Average
5-day SMA crosses below 20-day SMA
--
Bearish
NGNE Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Neurogene Inc(NGNE), our algorithm predicts NGNE's 1-month price at $18.60, with an -5.88%downwardshift. Using a similarity score up to 94.93%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Neurogene Inc (NGNE.O) stock, as of Sunday, June 15, 2025 , forecasts a -5.88% change over the next month, based on its high correlation with CRDF.O stock patterns. The similarity between their price movements over the analyzed periods is 94.93%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
NGNE
No Data
CRDF
Down: -5.88%Similarity: 94.93%
Name
Similarity
Up/Down
CRDF.O
94.93%
-5.88%
BAK.N
94.15%
-23.03%
WEN.O
93.73%
+3.76%
HWC.O
93.71%
+11.51%
CUZ.N
93.42%
+20.65%
ROAD.O
93.35%
+22.24%
STZ.N
93.28%
+7.00%
KMPR.N
93.21%
-1.34%
HUBG.O
93.17%
+7.74%
TRI.N
93.12%
+5.98%
NGNE Seasonality Analysis
Based on NGNE's historical stock price data across all years, the probability of a positive return in June is40.00%, suggesting it maynotbe an ideal month to invest in NGNE. In contrast,Augustoffers the highest probability of positive returns at61.54%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Neurogene Inc (NGNE.O) stock in August has the highest probability of a positive return (61.54%), while October has the lowest probability (21.43%).
Performance Seasonality
The chart shows Neurogene Inc. (NGNE)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Neurogene Inc (NGNE.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. NGNE has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Neurogene Inc (NGNE.O) stock in a year?
The radar chart shows that buying Neurogene Inc (NGNE.O) stock in August has the highest probability of a positive return (61.54%), while October has the lowest probability (21.43%).
How has Neurogene Inc. (NGNE)'s stock price performed over the past three years?
NGNE's stock price rose by 91.88% in 2023,increased by 15.05% in 2024, and went down by 20.05% in 2025.
Bearish technical signals of NGNE include: MOM_10 < 0, 5-day SMA crosses below 20-day SMA.
Is NGNE a buy based on overall technical signals summary?
NGNE has 4 buy signals and 2 sell signals now. Overall the technical rating for NGNE is Buy . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of NGNE.
What is the trend of Neurogene Inc (NGNE)'s moving average?
Neurogene Inc's overall moving average trend leans more bearish as of June 20 2025, with 3 negative signals and 1 positive signal.
What is price prediction for NGNE stock next month?
The price prediction chart for Neurogene Inc (NGNE.O) stock, as of June 15 2025, forecasts a -5.88% change over the next month, based on its high correlation with CRDF stock patterns. The similarity between their price movements over the analyzed periods is 94.93%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for NGNE Stock?
### **Price Prediction for NGNE Stock in 2025**
NGNE stock is expected to reach **$25 - $28** by the end of 2025, driven by positive analyst sentiment and moderate technical indicators. The stock currently trades at **$19.91**, with a potential upside of **26-40%** based on analyst targets.
What is price prediction 2030 for NGNE Stock?
### **Price Prediction for NGNE Stock in 2030**
1. **Bullish Scenario**: NGNE stock could reach **$35** by 2030, driven by successful Phase 1/2 trial results for NGN-401 and potential partnerships or buyout interest.
2. **Bearish Scenario**: The stock may drop to **$25** if clinical trials face setbacks or funding challenges arise.
3. **Base Case**: A moderate price target of **$30** is reasonable, considering the company's pipeline potential and biotech sector trends.
**Reasons**:
- **Clinical Pipeline**: NGNE's focus on rare neurological diseases with unmet needs positions it well for growth.
- **Analyst Sentiment**: HC Wainwright & Co. recently lowered the price target to $45 but maintained a Buy rating, indicating confidence in the company's long-term potential.
- **Market Trends**: The biotech sector's volatility and the success of gene therapy companies could influence NGNE's valuation.